CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO) now offers a more compelling setup than GLP-1 category leader Eli Lilly (NYSE:LLY) after a peak-to-current decline of roughly 68% from Novo’s mid-2024 high near $127 to recent levels near $40.

Eli Lilly has more to offer than some investors realize.

The American Hospital Association has called on federal regulators to intervene after Eli Lilly sent warning letters to 340B hospitals threatening to cut off discounted drug pricing unless they submit detailed claims-level data through a third-party platform.

Eli Lilly is set to post earnings Thursday morning, with the stock seen potentially sinking to its lowest level in months following the report.

Eli Lilly & Company (LLY) is a global pharmaceutical powerhouse that has redefined modern medicine through its leadership in neuroscience, oncology, and immunology. Lilly has transitioned from a traditional drug manufacturer into a high-growth biotech innovator,

Eli Lilly (LLY 2.56%) has established itself as the leader in the weight-loss drug market. Since this area is projected to grow significantly over the next decade, the company's o

Eli Lilly on Monday announced new price cuts for its popular weight loss drug Zepbound, broadening access for patients and driving greater use of the company’s digital healthcare platform, LillyDirect. Single-dose vials of Zepbound purchased through the ...

Evan Seigerman, BMO Capital Markets senior pharma analyst, joins 'Power Lunch' to discuss Seigerman's thoughts on Eli Lilly's earnings results.

By Christy Santhosh April 27 (Reuters) - Eli Lilly said on Monday it would buy privately held cancer drug developer Ajax Therapeutics for up to $2.3 billion in cash, as the U.S. drugmaker looks to expand its oncology pipeline.

Eli Lilly shares jumped after the drugmaker posted earnings that topped estimates and hiked its outlook, thanks to booming sales of its weight-loss drugs.

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.